Arcus Biosciences, Inc. — Director's Dealing 2020

Dec 19, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2020-12-17

Reporting Person: PERLMAN ANDREW J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-17	Common Stock	A	4500	$0.00	Acquired	4500	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-17	Stock Option (Right to Buy)	$31.77	A	21000	Acquired	2030-12-16	Common Stock (21000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2525	Direct

Footnotes

F1: Represents the grant of restricted stock units that vest in three equal annual installments on each of December 15, 2021, December 15, 2022 and December 15, 2023, subject to the Reporting Person's continued service to the Company.

F2: The option is exercisable in 36 equal monthly installments after December 17, 2020, subject to the Reporting Person's continued service to the Company.